menu
    • menu

    Company profile for Nexalin Technology

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Nexalin Technology is a non-invasive and drug-free therapy for those living with anxiety, depression and/or insomnia. Nexalin’s Patented Waveform (1 U.S. Patent #6904322B2) The Nexalin device produces a patented waveform that provides Transcranial Electrical Stimulation (TES). In clinical trials, this unique waveform resulted in the greatest increase in beta-endorphins. The Nexalin device has undergone extensive safety...
    Nexalin Technology is a non-invasive and drug-free therapy for those living with anxiety, depression and/or insomnia. Nexalin’s Patented Waveform (1 U.S. Patent #6904322B2) The Nexalin device produces a patented waveform that provides Transcranial Electrical Stimulation (TES). In clinical trials, this unique waveform resulted in the greatest increase in beta-endorphins. The Nexalin device has undergone extensive safety analysis with the results clearly indicating that the device is safe for its intended use. Additionally, the FDA classification of the device for clinical trials places it into a non-significant risk (low risk device).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nexalin TechnologyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1776 Yorktown St, Ste 550A, Houston, Texas 77056
    Telephone
    Telephone
    713 660 1100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://nexalin.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/nexalin-technology/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Arvo

    Arvo

    Not Confirmed

    envelop Contact Supplier

    Arvo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nexalin Publishes Neuroimaging Data On Chronic Insomnia Therapy
    Nexalin Publishes Neuroimaging Data On Chronic Insomnia Therapy

    28 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/28/3282788/0/en/nexalin-announces-peer-reviewed-publication-with-neuroimaging-data-in-psychotherapy-and-psychosomatics-highlighting-brain-network-effects-and-clinical-improvement-in-chronic-insomn.html

    GLOBENEWSWIRE
    28 Apr 2026
    Share Share
    Nexalin Progresses FDA Alzheimer's Strategy Post Key Leadership
    Nexalin Progresses FDA Alzheimer's Strategy Post Key Leadership

    15 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/15/3274605/0/en/Nexalin-Advances-FDA-Alzheimer-s-Strategy-Following-Landmark-Leadership-Meetings-in-the-U-S-and-China.html

    GLOBENEWSWIRE
    15 Apr 2026
    Share Share
    Nexalin Hosts Live Investor Webinar On April 21
    Nexalin Hosts Live Investor Webinar On April 21

    14 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/14/3273375/0/en/Join-Nexalin-s-Exclusive-Live-Investor-Webinar-and-Q-A-Session-on-April-21.html

    GLOBENEWSWIRE
    14 Apr 2026
    Share Share
    Nexalin Study Reveals DIFS Tech Cuts Self-Injury, Depression
    Nexalin Study Reveals DIFS Tech Cuts Self-Injury, Depression

    09 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/09/3270844/0/en/Nexalin-Announces-Peer-Reviewed-Study-Showing-the-Company-s-DIFS-Technology-Reduced-Self-Injury-and-Depression-Symptoms-in-Female-Adolescents.html

    GLOBENEWSWIRE
    09 Apr 2026
    Share Share
    Nexalin Participates in and Commends Recent Momentum Supporting
    Nexalin Participates in and Commends Recent Momentum Supporting

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242614/0/en/Nexalin-Participates-in-and-Commends-Recent-Congressional-Momentum-Supporting-Deep-Brain-Neurostimulation-Research-for-Veterans-and-Neurological-Disorders.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Nexalin Launches NeuroCare for Alzheimer's and Mood Disorders
    Nexalin Launches NeuroCare for Alzheimer's and Mood Disorders

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3233011/0/en/Nexalin-Launches-NeuroCare-an-AI-Driven-Virtual-Clinic-Designed-to-Transform-Access-for-Patients-with-Alzheimer-s-Mood-Disorders-TBI-PTSD-Care.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search